Projects

1 - 10 of 355 results

Sorteren op
Search term:

ORDECA – ORganoid Drug screening for Endometrial CAncerIdentifying novel drugs and biomarkers for treating endometrial cancer using a high-throughput patient-derived organoid drug discovery and screening platform KU Leuven

Hugo Vankelecom
Stem Cell and Developmental Biology, Molecular Virology and Gene Therapy, Gynaecological Oncology
Cancer of the womb’s inner lining (i.e. endometrial cancer, EC) is the most common gynecological malignancy and third cause of cancer-related death in women. Indeed, current treatments, typically surgical tumor removal and radio-/chemotherapy, remain inadequate in a high number of cases, frequently followed by recurrence of the cancer. Indeed, effective therapy of EC represents a high unmet clinical need in the women’s health domain. We ...

CD3 - the Centre for Drug Design and Discovery – discovering new drugs based on innovative research KU Leuven

Koenraad Debackere
Department of Management, Strategy and Innovation, Leuven, Intellectual Property

Het Centre for Drug Design and Discovery (CD3) is een drug discovery centrum en investeringsfonds dat focust op de transformatie van innovatief basisonderzoek naar klinische toepassing. CD3’s activiteiten zijn steeds gebaseerd op een samenwerkingsmodel met academische onderzoeksgroepen en biotech/pharma partners om samen nieuwe geneesmiddelen te ontwikkelen. Het ervaren drug discovery team van CD3 investeert in bedrijven en in vroege drug ...

Zebrafish platform for neuroactive drug discovery and safety assessment KU Leuven

Annelii Ny
Molecular Biodiscovery
This project aims at establishing a validated and high-throughput zebrafish-based platform implementing specific disease and toxicity models, with the purpose to create a viable spin-off company. The platform has a focus on phenotypic drug discovery for neurological diseases, an approach proven more successful in identifying novel drugs affecting the CNS compared to targeted drug discovery. It also provides the opportunity to assess the safety ...

Drug discovery and gene therapy KU Leuven

Veerle Baekelandt
Molecular Virology and Gene Therapy, Laboratory of Cellular Transport Systems, Research Group for Neurobiology and Gene Therapy

This valorization program covers an integrated strategy for disease model development, drug discovery and gene therapy approaches. The program is actively exploiting viral vector technology for the development and validation of screening platforms and model systems for drug discovery and gene therapy. The resulting platforms are subsequently advanced in dedicated valorization trajectories. The viral vector technology and services, developed ...

Next Generation Screening in Quantitative Biology & Drug Discovery KU Leuven

Catherine Verfaillie
Stem Cell and Developmental Biology, Switch Laboratory (VIB-KU Leuven)

In this proposal we outline a state-of-the-art platform that would be among the first in Europe to combine the best in automated microscopy with advanced cell culture robotics capable of automated isolation, expansion and differentiation of mammalian and human cells, including iPSC. The platform will be unique in Flanders and will allow running quantitative image-based screens as well as screens for disease phenotypes using conventional cell ...

From target identification to drug discovery KU Leuven

Zeger Debyser
Molecular Virology and Gene Therapy

Preclinical drug discovery from target validation, through assay development and biological profiling of novel hit and lead compounds. As such, we address different research areas including (1) HIV treatment and (functional) cure, (2) leukemia and in particular Mixed Lineage Leukemia, (3) Cystic Fibrosis and (4) Rett and MeCP2 Duplication syndrome. In collaboration with medicinal chemists and structural biologists we develop IP in these areas ...

Active learning and interpretation of computational model on tissue specific permeability for stock and virtual drug discovery library KU Leuven

Yves Moreau
Dynamical Systems, Signal Processing and Data Analytics (STADIUS), Budapesti Mûszaki és Gasdasagtudomanyi
One of the critical points in the discovery phase of drug research is the selection of a relatively narrow collection of samples from a large number of available and virtual compounds that provide sufficient chemical information to identify effective chemical structures at the given biological target after high-throughput biological screening (HTS). In this process, the increasing costs with numbers of measurement and the inherent need of ...

Zebrafish platform for drug discovery and safety testing KU Leuven

Peter de Witte
Molecular Biodiscovery

The academic research activities of the Laboratory for Molecular Biodiscovery are focused on generating tailor-made zebrafish models of human diseases and zebrafish toxicity reporter lines with high valorisation potential. In a first valorization trajectory zebrafish models of human diseases (with an unmet clinical need) are used to discover novel lead compounds from libraries accessible via ...

Advanced 3D Complex Tissues BioAssembly Platform for Precision Disease Modeling, Drug Discovery and Regenerative Medicine (3D-BioBOT) KU Leuven

Maurilio Sampaolesi
Translational Research in GastroIntestinal Disorders, Woman and Child, Stem Cell and Developmental Biology
This 3D-BioBOT project aims at establishing an advanced 3D bioassembly platform with broad deployability in KUL to generate robust in vitro human-cognate multicellular and organoid models that enable precision disease modeling, drug discovery and regenerative medicine. Currently, the models’ fidelity relies on spontaneous cellular self-organizations which often lead to uncontrolled heterogeneous tissue constructs with limited cell-to-cell ...

Validation of autophagy induction as a therapeutic strategy: from drug discovery and preclinical evaluation to safety investigation and biomarker research. University of Antwerp

Pieter Van Der Veken
Molecular Imaging and Radiology (MIRA), Toxicological Centre, Physiopharmacology (PHYSPHAR), Peripheral Neuropathies Group, Medicinal Chemistry (UAMC)
Autophagy is a ubiquitous process that removes unnecessary or dysfunctional cellular components from the cytoplasm. Defective autophagy is currently emerging as a hallmark of many diseases. In this framework, there is strong interest in pharmacological agents that stimulate autophagy (so-called 'autophagy inducers'), as a potential treatment for these diseases. The unequivocal validation of autophagy induction as a therapeutic strategy, however, ...